Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSM Insmed	$102.56 -1.5%	$86.93	$60.40 ▼ $106.83	$19.46B	0.9	2.29 million shs	1.43 million shs
LNTH Lantheus	$70.18 -4.6%	$78.80	$69.12 ▼ $118.21	$4.86B	0.12	978,301 shs	1.35 million shs
SMMT Summit Therapeutics	$26.20 -5.2%	$22.82	$8.80 ▼ $36.91	$19.46B	-1.01	3.75 million shs	3.00 million shs
TEVA Teva Pharmaceutical Industries	$16.08 -1.4%	$17.01	$12.47 ▼ $22.80	$18.44B	0.6	10.30 million shs	12.14 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSM Insmed	0.00%	+4.46%	-0.12%	+47.55%	+35.00%
LNTH Lantheus	0.00%	-13.69%	-11.38%	-30.25%	-39.91%
SMMT Summit Therapeutics	0.00%	+4.80%	+27.43%	+3.89%	+198.24%
TEVA Teva Pharmaceutical Industries	0.00%	-1.89%	-5.23%	+20.90%	-4.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSM Insmed	3.9583 of 5 stars	2.5	4.0	4.3	2.8	1.7	0.6
LNTH Lantheus	4.6057 of 5 stars	3.4	2.0	4.2	3.3	2.5	1.9
SMMT Summit Therapeutics	3.0678 of 5 stars	4.4	3.0	0.0	2.1	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.2358 of 5 stars	4.6	4.0	0.0	2.3	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSM Insmed	3.00	Buy	$108.47	5.76% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	86.95% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	32.32% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	53.70% Upside

Current Analyst Ratings Breakdown

Latest LNTH, INSM, SMMT, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSM Insmed	$363.71M	53.49	N/A	N/A	$1.60 per share	64.10
LNTH Lantheus	$1.53B	3.17	$7.10 per share	9.89	$15.65 per share	4.48
SMMT Summit Therapeutics	$700K	27,797.08	N/A	N/A	$0.53 per share	49.43
TEVA Teva Pharmaceutical Industries	$16.54B	1.11	$3.37 per share	4.77	$4.74 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	19.94	11.12	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.11	0.94	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest LNTH, INSM, SMMT, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSM Insmed	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSM Insmed	11.38	5.86	5.44
LNTH Lantheus	0.49	5.74	5.46
SMMT Summit Therapeutics	N/A	10.63	10.63
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSM Insmed	N/A
LNTH Lantheus	99.06%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
INSM Insmed	3.00%
LNTH Lantheus	2.00%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

LNTH, INSM, SMMT, and TEVA Headlines

Recent News About These Companies

Sargent Investment Group LLC Reduces Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 20 at 9:10 AM | marketbeat.com

Teachers Retirement System of The State of Kentucky Acquires 184,100 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 20 at 8:38 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to "Hold" at Wall Street Zen

July 19 at 12:38 AM | marketbeat.com

AustralianSuper Pty Ltd Decreases Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 19 at 10:57 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stake Increased by Carnegie Lake Advisors LLC

July 19 at 9:11 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by Victory Capital Management Inc.

July 19 at 6:32 AM | marketbeat.com

Migdal Insurance & Financial Holdings Ltd. Buys 300,000 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 18 at 9:59 AM | marketbeat.com

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters

July 18 at 3:06 AM | fool.com

Envestnet Asset Management Inc. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 15, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Penserra Capital Management LLC

July 13, 2025 | marketbeat.com

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

July 11, 2025 | zacks.com

Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders

July 10, 2025 | msn.com

Teva (TEVA) Receives a Buy from Leader Capital Markets

July 10, 2025 | theglobeandmail.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Boosted by IFM Investors Pty Ltd

July 8, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

July 7, 2025 | marketbeat.com

Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)

July 7, 2025 | theglobeandmail.com

Teva Pharmaceutical Industries Ltd. ADR Stock Grades - Barron's

July 7, 2025 | barrons.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Teacher Retirement System of Texas Reduces Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 6, 2025 | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 41,600 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 5, 2025 | marketbeat.com

Harel Insurance Investments & Financial Services Ltd. Buys 22,044,407 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH, INSM, SMMT, and TEVA Company Descriptions

Insmed NASDAQ:INSM

$102.56 -1.61 (-1.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$102.66 +0.10 (+0.10%)

As of 08:24 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Lantheus NASDAQ:LNTH

$70.18 -3.42 (-4.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$71.00 +0.81 (+1.16%)

As of 08:20 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$26.20 -1.43 (-5.18%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.34 +0.15 (+0.55%)

As of 08:13 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.08 -0.23 (-1.41%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$16.29 +0.21 (+1.31%)

As of 08:24 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time